Aducanumab, gantenerumab, BAN2401, and ALZ-801 – The first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval - Tolar, M; Abushakra, S; Hey, J A (Alzheimer’s Res Ther, 2020)
et al.